TWiV reviews a Lassa virus mRNA vaccine that confers protection against disease without inducing neutralizing antibodies, and a CRISPR-based method for engineering the genome of RNA viruses.
In his weekly clinical update, Dr. Griffin discusses the immunogenicity and reactogenicity of coadministration of COVID-19 and Influenza vaccines, interim effectiveness estimates of 2023 southern hemisphere influenza vaccines in preventing Influenza-associated hospitalizations, genome-wide association study of susceptibility to RSV hospitalization in young children <5 years of age, performance of rapid antigen tests to detect symptomatic and asymptomatic SARS-CoV-2 infection, safety and immunogenicity of XBB.1.5-containing mRNA vaccines, optimal duration of systemic corticosteroids in COVID-19 treatment, timing and predictors of loss of infectivity among healthcare workers with mild primary and recurrent COVID-19, and effects of famotidine on cognitive and behavioral dysfunctions induced in post-COVID-19 infection.
From the European Society for Clinical Virology meeting in Milan, Vincent speaks with Marion Koopmans about COVID-19, Mpox, H5N1 and polio, and the promise of a One Health approach to prevent outbreaks, epidemics, and pandemics….
In his weekly clinical update, Dr. Griffin discusses China’s health authorities fighting surge in cases of Mpox unknown origin, analysis of seasonal variation of antibiotic prescribing for respiratory tract diagnoses in primary care practices, prevalence and associated outcomes of co-infection between SARS-CoV-2 and influenza, comparison of bivalent and monovalent mRNA vaccine boosters, optimal duration of systemic corticosteroids in COVID-19 treatment, acute blood biomarker profiles predict cognitive deficits 6 and 12 months after COVID-19 hospitalization, temporal changes in fecal microbiota of patients infected with COVID-19, and long-term survival after intensive care for COVID-19.
Vincent speaks with Raul and Kostya about the development of novel oral polio vaccine from the Sabin type 2 strain, its deployment in over 600 million children, and whether it can lead to eradication of poliomyelitis.
In his weekly clinical update, Dr. Griffin discusses the public health significance of finding autochthonous melioidosis cases in the continental United States, human neural larva migrans caused by Ophidascaris robertsi ascarid, Project nextgen awards over $1.4 billion to develop the future of COVID-19 vaccines and therapeutics, excess all-cause mortality in China after ending the zero COVID policy, international pediatric COVID-19 severity over the course of the pandemic, differences in SARS-CoV-2 specific humoral and cellular immune responses after contralateral and ipsilateral COVID-19 vaccination, Pfizer and BioNTech receive positive CHMP opinion for Omicron XBB.1.5-adapted COVID-19 vaccine in the European Union, clinical antiviral efficacy of Remdesivir in COVID-19, optimal duration of systemic corticosteroids in COVID-19 treatment, clinical outcomes associated with overestimation of oxygen saturation by pulse oximetry in patients hospitalized with COVID-19, risk of autoimmune diseases following COVID-19 and the potential protective effect from vaccination.
TWiV describes how a viral capsid protein activates a bacterial innate immune system that interferes with protein synthesis, and human-associated redondoviruses that infect the commensal protozoan Entamoeba gingivalis.
In his weekly clinical update, Dr. Griffin discusses modeling poliovirus transmission and responses in New York State, FDA approves first vaccine for pregnant individuals to prevent RSV in infants, prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Cmmittee on Immunization Practices, Nirmatrelvir resistance – de novo E166V/L50V mutations in an immunocompromised patient treated with prolonged nirmatrelvir/ritonavir monotherapy leading to clinical and virological treatment failure, incidence of new-onset hypertension post–COVID-19: comparison with influenza, and post-acute sequelae of COVID-19 at 2 years.
TWiV reviews evidence that symptomatic adenovirus infection leads to thrombocytopenia, thrombosis, and production of anti-platelet factor 4 antibodies similar to the rare disorder seen after immunization with adenoviral vectored COVID-19 vaccines, and a monoclonal antibody isolated from a SARS survivor, following vaccination with a SARS-CoV-2 spike mRNA vaccine, that neutralizes a broad collection of ACE2-binding sarbecoviruses..
In his weekly clinical update, Dr. Griffin discusses Florida local transmission of dengue cases reported in Broward and Miami-Dade counties, infants admitted to US intensive care units for RSV infection during the 2022 seasonal peak, long-term risk of death and readmission after hospital admission with COVID-19 among older adults, safety profile and clinical and virological outcomes of Nirmatrelvir-Ritonavir treatment in patients with advanced chronic kidney disease and COVID-19, Fluvoxamine vs placebo for outpatients with symptomatic COVID-19, the effect of corticosteroids, antibiotics, and anticoagulants on the development of post-COVID-19 syndrome in COVID-19 hospitalized patients 6 months after discharge, long COVID and significant activity limitation among adults, incidence of diabetes following COVID-19 vaccination and SARS-CoV-2 infection in Hong Kong, and diabetes following SARS-CoV-2 infection: Incidence, persistence, and implications of COVID-19 vaccination.
The Hosts of TWiV
Vincent Racaniello, Ph.D.
Dickson D.
Despommier, Ph.D.
Alan Dove, Ph.D.
Daniel Griffin, M.D.,
Ph.D., CTropMed CTH
Jolene Ramsey, Ph.D.